Company news

Certara, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Certara to Participate in the Jefferies Global Healthcare Conference

May 28, 2024

Certara Appoints New Chief Human Resources Officer & General Counsel

May 20, 2024

Certara Reports First Quarter 2024 Financial Results

May 6, 2024

Certara Launches Cloud Platform to Further Unify its End-to-End Scientific Software Platform

April 15, 2024

Certara to Report First Quarter 2024 Financial Results on May 7th, 2024 and Participate in the BofA Securities Healthcare Conference

April 8, 2024

Certara Reports Fourth Quarter 2023 Financial Results

February 28, 2024

Certara to Report Fourth Quarter and Full Year 2023 Financial Results on February 29th, 2024 and Participate in the Barclays 26th Annual Global Healthcare Conference

January 31, 2024

Certara Acquires Applied BioMath Expanding Its Biosimulation Portfolio to Industrialize New Capabilities for Optimal Dosing for Novel Therapies

December 12, 2023

Certara introduces Simcyp™ Biopharmaceutics software to increase efficiency of novel and generic drug formulation & development

November 20, 2023

Certara Reports Third Quarter 2023 Financial Results

November 7, 2023

Certara to Report Third Quarter 2023 Financial Results on November 8th, 2023, and participate in the Stephens Annual Investment Conference

October 10, 2023

Certara Announces 300th Regulatory Submission Milestone Using its Technology-enabled Services and Software

September 18, 2023

Certara Simcyp™ Group Awarded Two New Grants from US FDA

August 28, 2023

Certara Reports Second Quarter 2023 Financial Results

August 8, 2023

Certara collaborates with Korea Institute of Toxicology to ensure FDA submission-ready SEND dataset

August 2, 2023

Certara to Report Second Quarter 2023 Financial Results on August 9th, 2023

July 12, 2023

Certara Reports First Quarter 2023 Financial Results

May 7, 2023

Certara Customers Received 90 Percent of US FDA Novel Drug Approvals for 9th Consecutive Year

April 26, 2023

Certara to Report First Quarter 2023 Financial Results on May 8th, 2023 and Participate in the BofA Securities 2023 Healthcare Conference

April 9, 2023

Xentria Announces Peer Reviewed Publication of Biosimulation Model in Frontiers in Pharmacology Journal

March 20, 2023

A.I. Coming to Certara’s D360 Scientific Informatics Software

March 8, 2023

Certara announces the release of Simcyp™ PBPK Simulator Version 22, expanding ability to simulate untested scenarios for new patient and therapeutic types

March 6, 2023

Certara Reports Fourth Quarter and Full Year 2022 Financial Results

February 28, 2023

Certara Announces Transition Plan for Chief Financial Officer

February 28, 2023

Certara to Participate in the Barclays Global Healthcare Conference

February 26, 2023

Certara to Report Fourth Quarter and Full Year 2022 Financial Results on March 1st, 2023

January 31, 2023

Certara Acquires Vyasa, an Artificial Intelligence Company that Delivers Predictions to Accelerate Scientific Innovation

January 3, 2023

Certara Announces the Completion of Arsenal Capital Partners’ Investment and the Appointment of David Spaight to the Board of Directors

December 7, 2022

Certara Reports Third Quarter 2022 Financial Results

November 6, 2022

Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) Renews Licenses of Certara’s Software for Evaluating Regulatory Submissions

October 18, 2022

Certara to Report Third Quarter 2022 Financial Results on November 7th, 2022

October 12, 2022

Certara Announces Secondary Offering

August 10, 2022

Certara Reports Second Quarter 2022 Financial Results

August 8, 2022

Certara Introduces Update of Pinnacle 21™ Enterprise and New Pinnacle 21™ Data Exchange Module

August 4, 2022

Certara Announces Collaboration with Leading Cancer Center to Advance CAR T-cell Therapies

July 27, 2022

Certara Appoints Rosemary Crane as New Independent Board Member

July 24, 2022

Certara Appoints Eran Broshy as New Independent Board Member

July 12, 2022

Certara to Report Second Quarter 2022 Financial Results on August 9th, 2022

July 11, 2022

Certara Introduces New Simcyp™ Discovery Simulator for Early-Stage and Translational Drug Development

June 27, 2022

Certara Announces New Versions of Biosimulation Software for Development of Novel Biologics

June 20, 2022

Certara Reports First Quarter 2022 Financial Results

May 4, 2022

Certara to Report First Quarter 2022 Financial Results on May 5th, 2022

April 19, 2022

Certara Reports Fourth Quarter and Full Year 2021 Financial Results

February 28, 2022

U.S. FDA Licenses Certara’s Immunogenicity Simulator

February 22, 2022

Certara Customers Received 90 Percent of US FDA Novel Drug Approvals for 8th Consecutive Year

February 14, 2022

Certara to Report Fourth Quarter and Full Year 2021 Financial Results on March 1st, 2022

February 7, 2022

Certara Announces FDA Renewal and Expansion of Certara’s Biosimulation Software for Reviewing Regulatory Submissions

December 20, 2021

Certara Announces Release of Pinnacle 21 Enterprise Software

December 12, 2021

Certara to Host Investor Day on December 15, 2021

December 7, 2021

Certara Announces Release of Simcyp™ Simulator Version 21, Expanding Capabilities to Align with Recent Regulatory Guidances

December 1, 2021

← Newer news releases · Older news releases →

Calls

The 5 newest of 21 calls. Every call is listed under its year.

Decks

The 5 newest of 31 decks. Every deck is listed under its year.